{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:43:38Z","timestamp":1784241818774,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["172033"],"award-info":[{"award-number":["172033"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jpba.2019.113034","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T13:05:32Z","timestamp":1575551132000},"page":"113034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Analytical quality by design development of an ecologically acceptable enantioselective HPLC method for timolol maleate enantiomeric purity testing on ovomucoid chiral stationary phase"],"prefix":"10.1016","volume":"180","author":[{"given":"Marija","family":"Mitrovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Proti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An\u0111elija","family":"Malenovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"Ota\u0161evi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Ze\u010devi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2019.113034_bib0005","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archopht.1977.04450040067008","article-title":"Timolol a \u03b2-adrenergic blocking agent for the treatment of glaucoma","volume":"95","author":"Zimmerman","year":"1977","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jpba.2019.113034_bib0010","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1001\/jama.1979.03290470051032","article-title":"Timolol in the treatment of open angle glaucoma","volume":"241","author":"Kosman","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.jpba.2019.113034_bib0015","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM198104023041401","article-title":"Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction","volume":"304","author":"The Norwegian Multicenter Study Group","year":"1981","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.jpba.2019.113034_bib0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM198401053100103","article-title":"Reduction of infarct size with the early use of timolol in acute myocardial infarction","volume":"310","author":"The International Collaborative Study Group","year":"1984","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.jpba.2019.113034_bib0025","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/bjo.64.4.240","article-title":"Timolol in operated closed-angle glaucoma","volume":"64","author":"Phillips","year":"1980","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jpba.2019.113034_bib0030","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2125.1987.tb03202.x","article-title":"Comparison of the airway response to eye drops of timolol and its isomer L-714,465 in asthmatic subjects","volume":"24","author":"Richards","year":"1987","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2019.113034_bib0035","series-title":"European Pharmacopoeia","year":"2017"},{"key":"10.1016\/j.jpba.2019.113034_bib0040","series-title":"U.S. Pharmacopeia National Formulary, USP 42\u2013NF 37, The United States Pharmacopeial Convention, North Bethesda, Maryland, United States","year":"2019"},{"key":"10.1016\/j.jpba.2019.113034_bib0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0021-9673(01)93275-3","article-title":"Direct separation and optimization of timolol enantiomers on a cellulose tris-3,5-dimethylphenylcarbamate high-performance liquid chromatographic chiral stationary phase","volume":"511","author":"Aboul-Enein","year":"1990","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2019.113034_bib0050","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/chir.530060607","article-title":"HPLC and NMR methods for the quantitation of the (R)-enantiomer in (-)-(S)-timolol maleate drug raw materials","volume":"6","author":"Lacroix","year":"1994","journal-title":"Chirality"},{"key":"10.1016\/j.jpba.2019.113034_bib0055","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/jssc.200301367","article-title":"LC method for the simultaneous determination of R-timolol and other closely related impurities in S-timolol maleate: optimization by use of an experimental design","volume":"26","author":"Marini","year":"2003","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2019.113034_bib0060","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.chroma.2006.03.104","article-title":"Nonaqueous capillary electrophoresis method for the enantiomeric purity determination of S-timolol using heptakis(2,3-di-O-methyl-6-O-sulfo)-\u03b2-cyclodextrin: validation using the accuracy profile strategy and estimation of uncertainty","volume":"1120","author":"Marini","year":"2006","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2019.113034_bib0065","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.chroma.2013.12.011","article-title":"Determination of (R)-timolol in (S)-timolol maleate active pharmaceutical ingredient: validation of a new supercritical fluid chromatography method with an established normal phase liquid chromatography method","volume":"1325","author":"Marley","year":"2014","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2019.113034_bib0070","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1039\/C5GC01008J","article-title":"CHEM21 selection guide of classical- and less classical-solvents\u2020","volume":"18","author":"Prat","year":"2016","journal-title":"Green Chem."},{"key":"10.1016\/j.jpba.2019.113034_bib0075","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0731-7085(92)80037-N","article-title":"Immobilized proteins as chromatographic supports for chiral resolution","volume":"10","author":"Narayanan","year":"1992","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.113034_bib0080","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jpba.2007.07.008","article-title":"Comparative study of immobilized 1 acid glycoprotein and ovomucoid protein stationary phases for the enantiomeric separation of pharmaceutical compounds","volume":"46","author":"Zhou","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.113034_bib0085","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.trac.2012.03.013","article-title":"Analytical Eco-Scale for assessing the greenness of analytical procedures","volume":"37","author":"Ga\u0142uszka","year":"2012","journal-title":"Trends Anal. Chem."},{"key":"10.1016\/j.jpba.2019.113034_bib0090","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jpba.2012.10.015","article-title":"Implementation of a design space approach for enantiomeric separations in polar organic solvent chromatography","volume":"74","author":"Nistor","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.113034_bib0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chroma.2014.12.065","article-title":"Quality by Design in the chiral separation strategy for the determination of enantiomeric impurities: development of a capillary electrophoresis method based on dual cyclodextrin systems for the analysis of levosulpiride","volume":"1380","author":"Orlandini","year":"2015","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2019.113034_bib0100","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s10337-016-3137-6","article-title":"Quality by Design-guided development of a capillary electrophoresis method for the chiral purity determination of ambrisentan","volume":"79","author":"Krait","year":"2016","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2019.113034_bib0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.chroma.2018.07.021","article-title":"Chiral capillary zone electrophoresis in enantioseparation and analysis of cinacalcet impurities: use of Quality by Design principles in method development","volume":"1568","author":"Pasquini","year":"2018","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2019.113034_bib0110","first-page":"1216","article-title":"System suitability and validation for chiral purity assays of drug substances","volume":"24","author":"Wrezel","year":"2006","journal-title":"LC GC N. Am."},{"key":"10.1016\/j.jpba.2019.113034_bib0115","unstructured":"International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite Guideline. Topic Q8 (R2): Pharmaceutical Development. ICH Expert Working Group, Geneva, Switzerland (August 2009)."},{"key":"10.1016\/j.jpba.2019.113034_bib0120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.trac.2017.10.028","article-title":"Quality by Design\u2019 approach for the analysis of impurities in pharmaceutical drug products and drug substances","volume":"101","author":"Dispas","year":"2018","journal-title":"Trends Analyt. Chem."},{"key":"10.1016\/j.jpba.2019.113034_bib0125","series-title":"Ultron ES-OVM Column: a Bonded Ovomucoid Protein Column for Direct HPLC Separation of Chiral Compounds","year":"2008"},{"key":"10.1016\/j.jpba.2019.113034_bib0130","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.chroma.2011.05.102","article-title":"Innovative high-performance liquid chromatography method development for the screening of 19 antimalarial drugs based on a generic approach, using design of experiments, independent component analysis and design space","volume":"1218","author":"Debrus","year":"2011","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2019.113034_bib0135","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s10337-018-3545-x","article-title":"Simple and efficient solution for robustness testing in gradient elution liquid chromatographic methods","volume":"81","author":"\u0160ljivi\u0107","year":"2018","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2019.113034_bib0140","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0167-9473(01)00056-1","article-title":"Regression analysis of experiments with complex confounding patterns guided by the alias matrix","volume":"39","author":"Lawson","year":"2002","journal-title":"Comput. Stat. Data Anal."},{"key":"10.1016\/j.jpba.2019.113034_bib0145","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10337-018-3661-7","article-title":"Robust optimization of chaotropic chromatography assay for lamotrigine and its two impurities in tablets","volume":"82","author":"\u010colovi\u0107","year":"2019","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2019.113034_bib0150","unstructured":"International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite Guideline. Topic Q2 (R1): Validation of Analytical Procedures: Text and Methodology. ICH Expert Working Group, Geneva, Switzerland (November 2009)."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519322630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519322630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:53:14Z","timestamp":1778543594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708519322630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":30,"alternative-id":["S0731708519322630"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2019.113034","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analytical quality by design development of an ecologically acceptable enantioselective HPLC method for timolol maleate enantiomeric purity testing on ovomucoid chiral stationary phase","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.113034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113034"}}